
Ipsen given an adcomm date for palovarotene; Ambrx Biopharma looks to secure $75M in latest securities offering
Ipsen has been given an advisory committee date of June 28 for its resubmitted NDA for palovarotene as a potential treatment for fibrodysplasia ossificans progressiva (FOP).
In December of last year, the FDA rejected the drug, asking for more data from its existing studies. But the agency is giving the French pharma another shot, setting a PDUFA date for Aug. 16, 2023, as more information on palovarotene’s clinical trial will be included in the resubmission. This comprises more analyses across the clinical trial program, including the first Phase III study that was carried out in patients.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters